Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts
10:19 ET--Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The drugmaker reported a first-quarter loss of $11.91 billion, or $5.89 per share, on revenue of $11.87 billion, with the loss reflecting the one-time net impact of acquired in-process research and development and licensing income related to recently closed transactions. Bristol Myers now expects full-year adjusted EPS in the range of 40 cents to 70 cents, down from $7.10 to $7.40 expected previously. The company is looking to save about $1.5 billion by the end of 2025 through a productivity initiative, which will impact about 2,200 jobs this year. Shares are down 7%. Dow Jones & Co. owns Factiva. (zaeem.shoaib@wsj.com)
(END) Dow Jones Newswires
April 25, 2024 10:38 ET (14:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025